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a b s t r a c t
National Immunization Technical Advisory Groups (NITAGs) provide independent, evidence-informed
advice to assist their governments in immunization policy formation. This is complex work and many
NITAGs face challenges in fulfilling their roles. Inter-country NITAG collaboration opportunities have
the potential to enhance NITAG function and grow the quality of recommendations. Hence the many
requests for formation of a network linking NITAGs together so they can learn from each other. The first
Global NITAG Network (GNN) meeting, held in 2016, led to a push to launch the GNN and grow the net-
work. At the second GNN meeting, held June 28–29, 2017 in Berlin, the GNN was formally inaugurated.
Participants discussed GNN governance, reflected on the April 2017 Strategic Advisory Group of Experts
(SAGE) on Immunization conclusions concerning strengthening of NITAGs and also shared NITAG expe-
riences in evaluation and inter-country collaborations and independence. They also discussed the role of
Regional Technical Advisory Groups on Immunization (RTAGs) and regional networks. A number of issues
were raised including NITAGs and communications, dissemination of recommendations and vaccine
implementation as well as implications of off-label recommendations. Participants were alerted to
immunization evidence assessment sites and value of sharing of resources. They also discussed potential
GNN funding opportunities, developed an action plan for 2017–18 and selected a Steering Committee to
help move the GNN forward. All participants agreed on the importance of the GNN and the value in
attracting more countries to join the GNN.
In 2017, National Immunization Technical Advisory Groups
(NITAGS) were recognized by the World Health Assembly as an
important element for a strong and effective immunization pro-
gram [1]. However, the development of evidence-based policy rec-
ommendations on the use of vaccines by a NITAG is complex, often
demanding work that requires not only quality data but also signif-
icant time and resources, and broad committee expertise [2]. In
2016, recognizing that NITAGs could potentially benefit from inter-
country collaboration, 26 countries met to discuss the formation of
a Global NITAG Network (GNN) [3]. Participants recommended
that a GNN be established and developed a proposed governance
structure. A small steering committee, one NITAG member from
each World Health Organization (WHO) region, was formed from
volunteers to advance the establishment of a GNN.
Following the first GNN meeting, work was carried out on the
GNN strategic document containing the network’s terms of refer-
ence. This document was reviewed by the steering committee
and experts from partner organizations for their input in advance
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of the second meeting. A logo for the GNN was designed and the
agenda for a second meeting developed. Over the year, the GNN’s
potential for moving forward and becoming formalized faced sev-
eral challenges including loss of members of the steering commit-
tee as several members rotated out of their country’s NITAG, hence
were no longer eligible, lack of financial resources and challenges
to secure secretariat support through partner institutions. Despite
these obstacles, a second meeting took place in Berlin on 28–29
June 2017 hosted by the Robert Koch Institute with the support
of the German Federal Ministry of Health. Funding from the
WHO to support attendance was available for a limited number
of countries. WHO, the United States Centers for Disease Control
and Prevention, the Robert Koch Institute and the Agence de Med-
icine Preventive Health Policy and Institutional Development
(AMP-HPID) provided technical and program planning support.
Twenty-six countries attended with a NITAG member or chair
and/or a representative from the NITAG secretariat (for these and
other attendees see Table 1).
During the meeting the following ten areas were addressed:
1. GNN governance and formalization of the GNN
While respecting each NITAG’s autonomy, the participants
finalized, with some minor modifications, the GNN governance
document that had been shared with all participants ahead of
the meeting [4]. Participants emphasized that this was not a static
document but one that will change over time as the GNN evolves.
The contribution of the GNN in promoting NITAG collaboration,
innovation and trends was highlighted as a major thrust. Countries
voluntarily participate in the GNN and there is not fee. Each mem-
ber country determines what NITAG relevant information, pro-
cesses and lessons learned will be shared and how this will be
done i.e. what materials added to the NITAG Resource Centre, what
shared directly with another country or countries and what not
shared. The GNN is not prescriptive to WHO regional NITAG net-
work functions nor in individual country NITAG decisions. The
WHO announced that it accepted the role of secretariat and would
provide for the main secretariat support. This is reflected in the five
page Strategic Document of the Global NITAG Network that outlines
Table 1
Participants in GNN Meeting, June 2017, Berlin Germany.
COUNTRY YEAR NITAG
ESTABLISHED
COUNTRY NITAG MEMBER OR CHAIR; OR NITAG SECRETARIAT
ALBANIA 2015 Najada Como, NITAG member; Iria Preza, NITAG Secretariat representative
ARGENTINA 2000 Pablo Bonvehi, NITAG Chair; Daniel Stecher, NITAG Secretariat representative
ARMENIA 2011 Anna Chobanyan, NITAG Chair; Gayane Sahakyan, NITAG Secretariat representative
AUSTRALIA 1997 Madeline Hall, NITAG Member
BELGIUM 1991 Yves Van Laethem, NITAG chair
CANADA 1964 Caroline Quach-Thanh, NITAG Chair; Gina Charos, NITAG NITAG Secretariat
representative
CHINA 1982 Feng Zijian, NITAG member
COSTA RICA 2001 Roberto Arroba, NITAG NITAG Secretariat representative
COTE D’IVOIRE 2009 Emmanuel Bissagnene, NITAG Chair; Issaka Tiembre, NITAG Secretariat
representative
EGYPT 2003 Hamed El-Khayat, NITAG secretariat representative
ETHIOPIA 2016 Yemane Berhane, NITAG Chair
FRANCE 1985 Daniel LEVY-BRUHL, NITAG member
GERMANY 1972 Thomas Mertens, NITAG Chair; Ole Wichmann, NITAG secretariat representative
INDIA 2001 Saurabh Gupta, NITAG Secretariat representative
JORDAN 2010 Najwa Kuri, NITAG Chair
MONGOLIA 2010 P.Nymadawa, NITAG Chair
MOZAMBIQUE 2011 Jahit Sacarlal, NITAG Chair; Antonio Nhambombe, NITAG secretariat representative
NEPAL 2010 Rupa Rajbhandari Singh, NITAG member; Rajendra Prasad Pant, NiTAG secretariat
representative
NETHERLANDS 1902 Gwen Soete, NITAG member
SAUDI ARABIA 2008 Aisha Alshammary, NITAG member
SENEGAL 2013 Mamadou BA, NITAG member
SPAIN 1991 Aurora Limia, Head of Area Immunization Program
SWEDEN 2016 Helen Englund, NITAG Secretariat representative
UNITED KINGDOM 1963 Anthony Harnden, NITAG Member, Andrew Earnshaw, NITAG secretariat
representative
VIET NAM 1998 Nguyen Minh Hang, NITAG secretariat; Nguyen Xuan Tung, NITAG secretariat
representative
ZIMBABWE 2011 N.A.Gonah, NITAG Chair
ORGANIZATION OTHER PARTICIPANTS
Dalhousie University, Canada Noni MacDonald, Meeting Chair and Facilitator
Robert Koch Institute Ole Wichmann, Carsten Martel, Sarah Wetzel
AMP- HPID Martin Mengel, HPID Director
Johns Hopkins University, USA Lois Privor-Dumm, RAVIN
London School Hygiene and Tropical Medicine, United
Kingdom
Helen Burchett, Sandra Mounier-Jack- SYSVAC
Partnership for Influenza vaccine introduction Jane Seward, consultant
USAID Endale Beyene, Immunization technical advisor
US-CDC Global Immunization Division Kathy Cavallaro, Abigail Shefer
Wellcome Trust, UK Alexis Gilbert, Specialty Registrar in Public Heath, Policy Unit
WHO Headquarters Philippe Duclos, Louise Henaff
WHO AFRO Blanche-Philomene Melanga Anya
WHO AMRO/PAHO Ana Gabriela Felix Garcia
WHO EURO Adam Finn, ETAGE Chair
WHO SEARO Gagandeep Kang, SEAR TAG
WHO WPRO Nyambat Batmunkh
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major points on Vision, Mission, Objectives; Values and Principles;
Type of Network and Regional Links as well as Membership, Func-
tions, Governance, Secretariat Functions and Sustainability and
Resilience [4]. The responsibilities of GNN Steering Committee
members, selection of a chair and the duration of terms were also
defined. As every country needs to participate and play a role in the
GNN, given the length of terms and the need for regional represen-
tation, every NITAG is expected to be on the steering committee
every 6 years or so. Developing the agenda for the annual GNN
meeting is the responsibility of the GNN Steering Committee along
with the Secretariat and includes suggestions from member
countries.
The ceremony to formalize the creation of the GNN took place
on the evening of the first day when Karin Knufmann-Happe for
the German Federal Ministry of Health gave the inauguration
speech and the GNN steering committee members signed the inau-
guration document. All participants at the meeting were invited to
sign the cover sheet. All documents will be held at WHO
headquarters.
2. Reflection on the April 2017 SAGE conclusions concerning
strengthening of NITAGs
The participants deliberated and commented on WHO’s Strate-
gic Advisory Group of Experts (SAGE) on Immunization recommen-
dations on NITAG that had been issued in April 2017 [5]. These
highlighted the importance of NITAGs as core institutions for
immunization program success and of the need for countries,
WHO, global partners and the donor community to continue to
provide support and facilitate their work. SAGE noted that while
good progress has been made in the number of countries having
met the six process indicators (Table 2) for the functioning of
NITAGs, the trajectory for meeting the 2020 global goal of all coun-
tries having a functional NITAG is still off track. The interactive
map available on the NITAG Resource Centre (NRC) site (http://
www.nitag-resource.org/who-we-are, accessed October 2017) pro-
vides information on which countries have a NITAG, when the
NITAG was created and if it meets some or all of the six process
indicators noted in Table 2. The interactive map also notes what
materials have been contributed to the NRC by a country. Small
countries are particularly lagging in NITAG formation and many
countries who do have a NITAG are not able to meet the conflict
of interest process indicator. SAGE also recognized the importance
of regional and global NITAG collaboration and recommended con-
tinuous support for the GNN and the NITAG Resource Centre (NRC)
(http://www.nitag-resource.org/, accessed October 2017). The NRC
is an interactive collaborative web platform, established in 2014,
that is a gathering place for all NITAG related information [7]. It
makes available all publications produced by NITAGs as well as
technical reports from partners and scientific publications useful
to NITAG members. As of September 2017, the NRC has been sup-
ported and managed by WHO.
During the second GNN meeting, participants underlined the
value of information-sharing amongst NITAGs especially via the
NRC and of funding support of NITAGs for their formation and
for support of their work in country. Potential solutions raised by
participants for the countries with small populations included
the use and adaptation of recommendations from a neighboring
country’s NITAG that they can relate to, partnership with another
NITAG or the formation of a sub-regional group of small countries
where recommendations could be developed jointly and then
shared in the member countries. Some NITAGS take the SAGE
reviews, ascertain how relevant the epidemiology and context for
the vaccine are to their population and then craft a recommenda-
tion but this can be problematic if specific vaccine preventable dis-
ease data is lacking. Another area of concern was the difficulty in
conducting systematic reviews when there is a lack of relevant
data and the resources/expertise to do the reviews are limited. This
undermines a NITAGs ability to produce evidence-based
recommendations.
3. Sharing of NITAG experiences in evaluation and inter-country
collaborations
The following are examples of success stories shared during the
meeting.
During a moderated discussion, Mozambique, Cote d’Ivoire and
Armenia each shared their experiences with external evaluation of
their NITAG using the NITAG Evaluation tool developed by AMP-
HPID (http://www.nitag-resource.org/media-centre/document/
1517-evaluation-tool-for-national-immunization-technical-advi-
sory-groups-nitags). This NITAG Evaluation tool focuses on assess-
ment of three areas: (1) functionality: do NITAG’s structure and
operations foster the timely generation of recommendations, (2)
quality: has the NITAG developed formalized and implemented
appropriate processes to ensure quality recommendations and
(3) integration: is the NITAG fully integrated into the decision mak-
ing system. The structured tool provides a template and guidance
on data to be collected in these three areas, how to analyze and
assess the data and on how to present the results.
Use of this tool enabled these three NITAGs to identify gaps and
work on potential solutions. Mozambique, for example, now uses
graduate students under the guidance of a NITAG working group
to help develop required systematic reviews. This has expanded
expertise and the time available to commit to the reviews as well
as helping to prepare potential future members for the NITAG.
Australia noted that they were using the NITAG Evaluation tool
for self-evaluation to good effect.
The value and success of cross country collaborations was also
highlighted by the panel. The Chair from the Mozambique NITAG
was involved in the establishment of the NITAG in Angola and par-
ticipated in the training of members of their newly established
NITAG. The Chinese representative reported on the study tour of
the Chinese NITAG members to the US and Canadian NITAGs in
September 2016 and the workshop in China where NITAG mem-
bers from the United Kingdom, the United States and from
Germany were invited to share their expertise in NITAG function-
ing and help China build up their new NITAG structure. The Aus-
tralian NITAG participant noted that their NITAG has endorsed a
strategic document stating that international collaboration was
an asset and that they were committed to foster it and work with
NITAGs in other countries (http://www.immunise.health.gov.au/
internet/immunise/publishing.nsf/Content/FC7BB2DC63225F8A-
CA257D770012DBF7/$File/ATAGI-Strategic-Intent.pdf). Saudi
Arabia noted that with the approval of their Ministry, the NITAG
is planning to post documents on a website to promote the work
Table 2
Six Process Indicators for functioning NITAG; assessed annually in the WHO UNICEF
Joint Reporting Form [6].
Indicator
1 Legislative or administrative basis for the advisory group
2 Formal written Terms of Reference
3 Diverse expertise/representation among core members (in terms of
paediatrics, public health, infectious diseases, epidemiology, immunology
or other health-care professionals)
4 Number of meetings per year
5 Circulation of the agenda and background documents at least one week
prior to meetings
6 Mandatory disclosure of any conflict of interest
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of the committee. These are in Arabic and may well be helpful to
other Arabic speaking countries.
4. Discussion on the role of Regional Technical Advisory Groups
on Immunization (RTAGs) and regional networks
Following break out and then plenary discussions, the partici-
pants highlighted that NITAG chairs and secretariats as well as
GNN steering committee members should be encouraged to attend
RTAG meetings. The GNN should help regions access resources,
share data and make links between the regions, while Regional
NITAG Networks should encourage collaboration between NITAGs
in the region, mobilize resources, share challenges and information
with the GNN and participate in envisaged annual GNN meetings.
NITAGs need to be encouraged to link with other countries in their
region (and beyond) to work on the same topics and identify train-
ing opportunities. Virtual meetings could be set up for NITAGS in a
region as they are often in the same/similar time zone. The aim of
the regional NITAG networks is to bring together NITAGs from the
same region, exchange lessons learned, discuss challenges as well
as identify common priorities and resources that could be shared.
To date, only one WHO Region has a formally established regional
NITAG Network, the South East Asia Region. While Regional NITAG
Networks may not be possible in all regions, in several regions
NITAG chairs are systematically invited to the RTAG meetings as
a means of supporting learning and sharing of information. Partic-
ipants emphasized the importance of collaboration beyond the
regions, through sharing materials and information via the NRC
as well as through direct country to country collaborations. By hav-
ing NITAGS share their work plans through the NRC, a NITAG
would know whom to turn to if necessary when starting work on
a new topic.
5. Sharing of NITAG experiences on independence
In a panel discussion, representatives from Belgium, Costa Rica,
Nepal and Canada shared how their NITAG functions, highlighting
how their committees balance independence from government
and integration of the NITAG decisions into government policy.
The models in the four countries showed marked contrasts empha-
sizing how one size does not fit all.
In Belgium the NITAG, which was established in 1991, is inde-
pendent but located within the Ministry of Health. Experts to serve
on the NITAG are approved by the Ministry of Health. The NITAG
decides on the work plan and responds to specific questions from
the Ministry of Health. The Working Groups are established by
the NITAG, develop consensus recommendations and report to
the High Council of Health and to the Ministry of Health, who then
have two weeks to decide on a response.
In contrast, in Costa Rica the NITAG, which was established in
2001, is presided over by the Minister of Health. The NITAG devel-
ops draft recommendations and collaborates closely with the Pan
American Health Organization to conduct cost-effectiveness
reviews. The results are presented to the Ministry of Health with
the recommendation of the NITAG. The Ministry of Health then
presents to the social security system who can decide on whether
to fund the vaccine. The Costa Rica NITAG acts as both a NITAG and
an Interagency Co-ordinating Committee. There are currently no
processes in place to assess and address conflicts of interest of
members but these are being developed.
Nepal provided an example of a NITAG with more indepen-
dence from the Ministry of Health. In Nepal the NITAG was estab-
lished in 2009 and it now fulfills all the six WHO indicators
(including the declaration of interests) and provides independent
technical guidance on optimal immunization to the Ministry of
Health. The NITAG is supported by a secretariat in the Ministry
of Health.
A further variation was provided by Canada whose NITAG dates
from 1964. All 14 NITAG members are appointed by the Public
Health Agency of Canada with the disciplines of members stated
in the terms of reference to ensure breadth and depth of member-
ship. Direct and indirect conflicts of interests must be disclosed, are
well scrutinized and then publically posted. The meetings are not
open to the public but several relevant specialist organizations
attend meetings as liaison members but are not allowed to vote.
There are also two reporting liaison seats for the Canadian pro-
vinces/territories. The NITAG provides recommendations to the
Public Health Agency of Canada but implementation is up to the
provinces as Canada is a federation with the provinces and territo-
ries responsible for health programs and delivery while the federal
level is responsible for guidance and standards making immuniza-
tion a shared jurisdiction.
6. Reflection on NITAG off-label recommendations
During the Canada NITAG presentation, it was noted that
NITAGs, based upon evidence, often make off-label recommenda-
tions on the use of vaccines that can be in conflict with those of
the National Regulatory Authorities for drugs including vaccines.
Off label use of vaccines means any use of an authorized product
not covered by the terms of its marketing authorization and thus
not in accordance with the monograph labelling [8]. This is the
case Canada. This precipitated a brisk participant discussion as
off-label recommendations have been prominent recently in many
NITAGs and in SAGE recommendations e.g. fractioning of doses of
injected polio vaccine doses and of yellow fever vaccine. Such
off-label decisions by NITAGs are important as the value of the
NITAG is to maximize the benefit and public health value of a given
vaccine in general or specific circumstances, including during vac-
cine shortages. However, this is a complex area with many facets
(e.g. liability of physicians and of manufacturers or lack of coverage
by insurance companies) that prevents NITAGs in some countries
from making off-label recommendations. The United States and
the United Kingdom NITAGs shared their respective experiences
with off-label recommendations. Both noted that their NITAGs
often make such recommendations when there is evidence sup-
ports these. In contrast, in Germany the NITAG can only issue
off-label recommendations under rare exceptions. More com-
monly, the manufacturer is asked to submit an application to the
respective regulatory authority to change the label (as successfully
happened with the licensure of Tdap-vaccines for the use in
pregnancy).
This discussion culminated with a proposal that it would be
beneficial if GNN members shared experiences and the evidence
on which off-label recommendations are based (e.g. systematic
reviews or single studies on alternative schedule or specific popu-
lations). Off-label use was then highlighted as a topic for the antic-
ipated 3rd GNN meeting.
7. Discussion of NITAG roles in communications, dissemination
of recommendations and vaccine implementation
Representatives from Mozambique, UK, Australia, and Germany
shared their lessons learned on communications and dissemina-
tion of recommendations with respect to building credibility and
trust in their NITAG.
In Mozambique, the NITAG holds more 10 meetings a year,
these are closed. The NITAG prepares an annual report to Ministry
of Health and also is active in disseminating recommendations
locally. All the recommendations are posted on the NRC. In the
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United Kingdom, the NITAG posts an interim statement and asks
for feedback on big decisions. Three meetings are held each year,
all closed but the minutes are published shortly after each meeting
on the Public Health England website. In Australia, the NITAG has a
self-developed work plan and holds three general meetings where
working parties present their findings and recommendations. The
meeting decisions are available online (http://www.immunise.
health.gov.au/internet/immunise/publishing.nsf/Content/atagi#
bulletins) and at the NRC. Pharmaceuticals companies are invited
to one special NITAG meeting each year where their scientists,
not their marketing people, outline new vaccine developments
and refinements. The NITAG recommendations inform the online
Australian immunization handbook which is updated twice a year.
The NITAG provides technical advice to the government and a sep-
arate committee the cost effectiveness. The government needs to
approve such recommendations and such approval can be delayed.
In Germany, the NITAG develops recommendations following a
standard operating procedure and applying evidence-based
methodologies. A draft recommendation and the respective back-
ground paper is sent to professional societies, the 16 federal states,
and the Federal Joint Committee (a self-government body of physi-
cians, dentists, hospitals and health insurance funds in Germany)
for review and comments within a 6-week period. The final deci-
sion is then independently published and does not require
endorsement by the Ministry of Health. Once in the schedule, this
forms the basis for vaccines to be paid for by the social insurance
companies. They have three months to decide on this but must
provide good reasons to reject. If a NITAG member has a conflict
of interest related to a vaccine under consideration, this person
leaves the room and cannot vote on issues related to the specific
vaccine. The meeting minutes are published online (www.stiko.
de/en) and since September 2016 as a pocketbook to be purchased
in book stores and on a smartphone app (STIKO.app; https://itunes.
apple.com/de/app/stiko-app/id1113590161?mt = 8 https://play.
google.com/store/apps/details?id = com.boerm.bruckmeier.robert_
koch_institut_stiko&hl = de), developed by the NITAG secretariat at
the Robert Koch Institute, mainly intended for use by physicians. It
contains recommendations and guidelines on how to implement
the recommendations and communication messages. The app also
includes around 230 frequently asked questions with answers,
push messages to inform about new recommendations and warn
about rumours, an algorithm on catch-up vaccination, and a
resource centre (e.g. advice on how to address vaccination argu-
ments). As of June 2017, the app has been downloaded by more
than 40,000 users.
Following this panel presentation in follow up to communica-
tion, participants stimulated lively a discussion on vaccine hesi-
tancy as NITAGs play an important role in addressing hesitancy.
The rates of vaccine refusal are quite low in Australia (5%). A web
page has been developed for the public (parents), presenting the
risks of not vaccinating and comparing this to the risks of vaccinat-
ing. In Australia, the legislation supports the NITAG. ‘‘No jab, no
pay” = no receive the child benefit funds if the child is not immu-
nized. ‘‘No jab, no play” = a child is no allowed to be enroll in
kindergarten or school if not vaccinated (http://www.ncirs.edu.
au/consumer-resources/no-jab-no-play-no-jab-no-pay-policies).
In the United Kingdom, Germany and Mozambique, the vaccine
refusal rates are also quite low. As hesitancy maybe due to con-
cerns about vaccine safety, panelists were asked if their NITAGs
have a representative from the vaccine safety program at the
NITAG meetings who report on safety issues. The United Kingdom
NITAG asks the safety program to give an update once a year. This
is included in the minutes that are published. This is similar for
Germany. Australia has a committee on vaccine safety and one
member sits on the NITAG and reports are included in the minutes.
Jordan raised the issue of bloggers who increase the anti-vaccine
sentiments. Panelists noted that engaging with conspiracy theo-
rists may increase anti-vaccine issue. However, giving access to
experts that the media can trust can enable the press to prevent
the media from publishing overt lies and having them cross-
check their information. The United Kingdom NITAG does contact
the press and are in regular touch with journalists.
8. Alert on evidence assessment and sharing of resources
The SYSVAC (http://Immunization.hpru.nihr.ac.uk/sysvac), a
database of systematic reviews on vaccines and Immunization
developed by the London School of Hygiene & Tropical Medicine,
has been integrated in the media centre of the NRC (http://www.
nitag-resource.org/). The SYSVAC database collects a list of all sys-
tematic reviews on human vaccines registered on Prospero,
Embase and Cochrane, including those on the epidemiology of
the target disease, vaccine safety, immunology, coverage and eco-
nomics. This integration within the NRC should make it easier for
NITAGs to search for systematic reviews. Currently the SAGE sys-
tematic reviews are not registered on Prospero yet and this needs
to be remedied by WHO. A representative from the German NITAG
secretariat shared experiences on how existing reviews can be uti-
lized in the process of assessing the available evidence as a basis
for a new recommendation [9]. Participants noted that such rigor-
ous assessment and review processes (e.g. review of systematic
reviews) need to be shared via the NRC. The NRC should regularly
send a list of updated resources to all GNN members, including
(but not only) systematic reviews including those done by SAGE.
9. Discussion on GNN funding and development of an action
plan
WHO provided a brief summary on support for the GNN secre-
tariat. The Supporting Independent Immunization and Vaccine
Advisory Committees (SIVAC) Initiative; to support the establish-
ment of NITAGS in low income countries and the development
and strengthening of NITAG tools to support NITAGs e.g. the NRC,
the NITAG evaluation tool; from the Bill and Melinda Gates Foun-
dation ended in 2016 [3]. Currently there are limited dedicated
resources to support the establishment of new NITAGs or for travel
of NITAG members to future GNN meetings. However, GAVI eligi-
ble countries can include the establishment of NITAGs in their
work plans which could ensure some targeted technical assistance
for the establishment and/or support of a NITAG. All countries
must be encouraged to fund and support a NITAG. This is backed
up by the 2017 World Health Assembly recommendation that
emphasizes the importance of NITAG work. Participants noted that
for the GNN, NRC and NITAGs to thrive there must be country and
partner support. While the NRC will now be supported by WHO,
further development and sustainability will require more
resources and support. The possibility of requesting funding from
professional societies to support the GNN and the NRC was put for-
ward for consideration. However, this was seen as concerning as
some societies may have received unrestricted funds from vaccine
manufacturers and hence have conflicts of interest. Many partici-
pants expressed discomfort with this option. Other sources need
to be sought.
An action plan for the GNN for the 2017–18 was developed by
participants with a priority focus on the NRC manager regularly
sending (a) reminders to NITAGS to share information via the
NRC and (b) the NITAGs the newest publications (recommenda-
tions, guidelines, systematic reviews) including those that are just
for members only on a regular basis; and for the GNN secretariat to
(a) undertake a survey of NITAGs on the usefulness of the NRC, (b)
develop a rolling list of key work plan elements of each NITAG and
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a global work plan noting which NITAGs is working on what topics
and (c) set up an index so NITAGS can contact other NITAGs work-
ing on the same subject and also stimulate development of topic
interest groups and for NITAGs. As well, member countries and
the GNN secretariat were pressed to work to increase GNN mem-
bership. Participants emphasized that more countries need to be
apprised of the GNN and that there is no membership fee to join.
The GNN needs to be discussed at RTAG meetings so more coun-
tries are alerted to it and to initiate discussions about the establish-
ment of regional networks and the role of RTAGs in such networks.
10. Selection of the steering committee members, alternates,
chair and deputy chair. Identification of priority activities for
the GNN and its global partners
As per the governance document, the GNN volunteer steering
committee members and alternates were approved with a chair
and vice-chair (see Table 3). Meeting participants suggested that
the Chair and Vice Chair be invited to attend the SAGE meetings.
Participants strongly supported having an annual GNN meeting.
A discussion ensued about the site and timing of the 2018 GNN
meeting. Given that the NITAG member and the country represen-
tative who come to the GNN must be self-funded, there was con-
cern that to date, the GNN meetings have only taken place in the
European Region. In order to make the GNN accessible to more
countries, participants suggested that meeting venues rotate from
region to region with the annual date for the GNN to be settled by
surveying the members. Participants emphasized the importance
of growing advocacy for the GNN and NRC in different settings as
GNN functions and NRC work must become a priority of WHO,
partners, donors and also for countries.
In conclusion, the GNN was formally launched in June 2017 has
a membership of 35 countries coming from all WHO Regions.
Given that there is no charge to join or belong to the GNN,
membership is expected to grow as NITAGs learn about the oppor-
tunity and value added of membership. As participants empha-
sized, the GNN provides an important forum for networking,
sharing lessons learned and NITAG documents, for developing
partners for NITAG evaluations and for wrestling with complex
issues such as how to manage conflicts of interest and off-label
use of vaccines. The 3rd GNN meeting is tentatively scheduled
for 26–27 June 2018.
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